Close Menu
Agricultural biotech firm Evogene announced this week that its second quarter revenues rose to $129,000 from $10,500 in the second quarter last year.
The Israeli firm posted a net loss of $738,000, or $.05 per share, for the three months ended June 30, compared with a net loss of $836,000, or $.06 per share, for the comparable period a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.